MEDICAL AESTHETICS, DERMATOLOGY, & NEUROMODULATORS
PHILIPPE
SCHAIISON
Executive Vice President &
President, Allergan Medical
OPEN SCIENCE in Action

Underlying Logic behind Aesthetics Strategy

Use Open Science Model to Sustain Leadership

Leading Therapies In:
- Facial Aesthetics
- Breast Implants
- Plastic Surgery
- Skin Medica

KYTHERA® BIOPHARMACEUTICALS

earfold™
Delivering and Building the Aesthetics & Dermatology and Neuromodulator Pipeline

- BOTOX Adult LL Spasticity (US) submitted July 2015
- BOTOX Submission in Japan for crow’s feet lines June 2015
- Volbella Lips and Volift – US PMA submission Q3 2015
- Voluma temple and Voluma chin – IDE submitted June 2015
- Juvéderm Lips – PMA approval September 2015
- Volite EU approval April 2015
- Natrelle Inspira™ round gel-filled implants – PMA Approval – Smooth & Textured – June 2015
- ACZONE® (dapsone) Reformulation US NDA submitted at end of April 2015
- Oxymetazoline Rosacea Phase 3 data
EARFOLD™ is a Medical Innovation to Correct Prominent Ears

- Acquired from Northwood October 2015
- Medical device indicated to correct prominent ears. Minimally invasive outpatient procedure compared to the current surgical procedure – otoplasty
- Otoplasty is the 10th most frequently performed aesthetic procedure
- >70% of otoplasty procedures are performed by Allergan customers, providing significant expense synergy
- EARFOLD is launch-ready in Europe (already available in the UK)
- FDA approval will require additional development activity
KYBELLA® Injection into Subcutaneous Fat Causes Cell Lysis

- KYBELLA contains synthetic deoxycholic acid
- When injected into subcutaneous fat, causes lysis of fat cells
- Inflammatory tissue response lasts ~28 days, MPs engulf the cellular debris and lipids removing them from the area
- Minimal residual inflammation and suggested increase in total collagen
KYBELLA: First Injectable Treatment for Submental Fullness (SMF)
~80% of Patients Responded to KYBELLA

- Clinician and patient ratings were congruent
- Ratings differed significantly between KYBELLA subjects and placebo subjects
- Many KYBELLA subjects experienced a ≥1 grade improvement in 2-4 treatments
KYBELLA Secondary Endpoints – Significant Improvements in Visual and Psychological Impact of Chin Fat

Lower scores indicate improvement or reduced negative impact of these items.
KYBELLA Has “Pipeline in a Product” Potential

KYBELLA Potential Extends into Targeted Areas of Small, Localized Fat

KYBELLA Potential to Extend into Therapeutic Applications

KYBELLA Planned for Global Rollout

**2015**
- ☑ US approved/launched
- ☑ Canada approved
- ☑ Australia filed
- ☑ EU Decentralized file Pool #1

**2016**
- ☐ Canada launch
- ☐ Australia launch
- ☐ Switzerland Approval
- ☐ EU Pool 1 approval
- ☐ EU DCP Pool 2 submission
- ☐ Brazil submission
- ☐ China CTA submission
- ☐ New Zealand submission

**2017**
- ☐ EU National launches
- ☐ New Zealand approval
Aesthetic Market Projected to Double by 2020

KYBELLA is the Most Innovative Technology in the Fast Growing Body Sculpting/Fat Market

Fat Reduction Expands Our Portfolio Offering

Non-invasive Fat Reduction

<table>
<thead>
<tr>
<th></th>
<th>Allergan</th>
<th>Galderma</th>
<th>Merz</th>
<th>Valeant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin Tightening</td>
<td>✓</td>
<td>×</td>
<td>×</td>
<td>✓</td>
</tr>
<tr>
<td>Fillers</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>×</td>
</tr>
<tr>
<td>Toxins</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>×</td>
</tr>
<tr>
<td>Topicals</td>
<td>✓</td>
<td>×</td>
<td>×</td>
<td>✓</td>
</tr>
<tr>
<td>Breast Implants</td>
<td>✓</td>
<td>×</td>
<td>×</td>
<td>×</td>
</tr>
</tbody>
</table>
# Market Leading Medical Aesthetics Portfolio

<table>
<thead>
<tr>
<th>Product</th>
<th>Area(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SkinMedica</td>
<td>Entire Face</td>
</tr>
<tr>
<td>Botox</td>
<td>Upper Face</td>
</tr>
<tr>
<td>Latisse</td>
<td>Eyes</td>
</tr>
<tr>
<td>Juvederm</td>
<td>Mid Face</td>
</tr>
<tr>
<td>Juvederm</td>
<td>Lower Face</td>
</tr>
</tbody>
</table>
| kybella     | • Lips
|             | • Chin/Neck      |
Hair Growth: 2 Early Programs with Positive Prospects

**Setipiprant (oral)**
- Orally active, selective and potent inhibitor of Prostaglandin D$_2$
- A physiological inhibitor of hair growth
- Elevated PGD$_2$ levels in balding scalp

**Bimatoprost (topical)**
- Synthetic prostamide analog of prostaglandin F2α
- Positive POC using a prototype formulation developed for scalp
- Enhanced delivery formulation being developed
- Ph 1 PK & Ph 2b studies planned Q1 2016

**PGD$_2$ Fold Change**

- Before
- After Bimatoprost 1%

**P**<0.01
Bimatoprost Scalp Hair Growth Still Early but Positive Results

Positive Proof of Concept using a prototype developed for scalp

% subjects with ≥ 1 grade improvement on scale of +3 to -3
Significant Hair Growth Market –
Unmet Need

Androgenic global hair growth mkt for
pharmaceutical products

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue</th>
<th>CAGR</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>$1.2B</td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>$1.6B</td>
<td>33%</td>
</tr>
</tbody>
</table>

Current Treatments

- Minoxidil (Rogaine®) & Propecia® account for ~$500M in global sales
- Typically recommended by a dermatologist
- Current Prescription treatments are perceived as stronger and more effective than OTCs but still limited in their effect
Oxymetazoline for Erythema of Rosacea Topical Treatment

- Affects >16M in US; Highest Prevalence Among Women, 30–50 Years Old
- Large population that is significantly undertreated due to lack of treatments specifically for Erythema
- Alpha1&2 adrenergic agonist that causes vasoconstriction of abnormally dilated blood vessels to reduce redness
- Oxymetazoline cream 1% is being developed for treatment of persistent facial erythema (redness) associated with rosacea
  - Phase 3 has been completed
  - 2 long-term safety studies met end point – high statistical significance
  - Favorable dermal safety profile compared to Mirvaso®
  - NDA submission targeted for Q1 2016
Oxymetazoline Cream 1% Demonstrated Efficacy and Patient Satisfaction

Efficacy Results

>2 grade Improvement on both Clinician and Subject’s Assessment on Day-29 compared to baseline

Percent of Patients Reporting “Satisfied” or “Very Satisfied” on Day 29

- Oxy 1.0% (N=222)
- Vehicle (N=218)

<table>
<thead>
<tr>
<th>Hours</th>
<th>Oxy 1.0%</th>
<th>Vehicle</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hour 3</td>
<td>45.9</td>
<td>27.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hour 6</td>
<td>43.7</td>
<td>24.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hour 9</td>
<td>43.2</td>
<td>23.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hour 12</td>
<td>41.9</td>
<td>24.8</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
Oxymetazoline 1% Safety Profile Demonstrates No Rebound Effect

### Oxymetazoline: AEs by >2% of Patients

<table>
<thead>
<tr>
<th>Adverse Event (Preferred Term)</th>
<th>Oxy 1.0%(N=440)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper respiratory tract infection</td>
<td>3.6%</td>
</tr>
<tr>
<td>Rosacea</td>
<td>3.2%</td>
</tr>
<tr>
<td>Application site dermatitis</td>
<td>3.0%</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>3.0%</td>
</tr>
<tr>
<td>Hypertension</td>
<td>2.5%</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>2.3%</td>
</tr>
<tr>
<td>Headache</td>
<td>2.3%</td>
</tr>
<tr>
<td>Application site pain</td>
<td>2.0%</td>
</tr>
<tr>
<td>Application site pruritus</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

### Mirvaso: AEs by >4% of Patients

<table>
<thead>
<tr>
<th>Preferred Term</th>
<th>Mirvaso (N=449)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flushing</td>
<td>10%</td>
</tr>
<tr>
<td>Erythema</td>
<td>8%</td>
</tr>
<tr>
<td>Rosacea</td>
<td>5%</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>5%</td>
</tr>
<tr>
<td>Skin burning sensation</td>
<td>4%</td>
</tr>
<tr>
<td>Increased intraocular pressure</td>
<td>4%</td>
</tr>
<tr>
<td>Headache</td>
<td>4%</td>
</tr>
</tbody>
</table>

Recreated from Mirvaso Label. Data presented for >4% of Patients only

### Much higher rates of discontinuations for Mirvaso (1-year long-term safety study for both)

<table>
<thead>
<tr>
<th>Patient Disposition (1-year safety)</th>
<th>Oxy 1%</th>
<th>Mirvaso</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premature discontinuation</td>
<td>17.0%</td>
<td>37.9%</td>
</tr>
<tr>
<td>Due to AEs</td>
<td>3.2%</td>
<td>16.7%</td>
</tr>
</tbody>
</table>

Much higher rates of discontinuations for Mirvaso (1-year long-term safety study for both)
Sarecycline Will Enter Allergan into a New Acne Category – Oral Antibiotic Market (US Market $1B+)

**Market Overview**

- Minocycline and Doxycycline are the two most commonly prescribed oral antibiotics for acne
- Solodyn® (minocycline) is the largest branded product sold, followed by Doryx® (doxycycline)

**Sarecycline**

- Sarecycline, a next generation tetracycline is currently in Phase 3
- May offer low GI side effects in a once a day treatment
- Flexible dosing: 60mg, 100mg, and 150mg
- Complement to topical ACZONE®, Tazorac®, & Azelex® acne portfolio

![Market Share Chart]
Data pooled from the two pivotal trials

**ACZONE 7.5% – Effective Once Daily for Acne Vulgaris**

Total lesion count reduction statistically significantly superior to vehicle starting as early as Week 4

![Graph showing mean percent reduction from baseline at weeks 0, 3, 6, 9, and 12 for ACZONE (n = 2162) and Vehicle (n = 2178). Key points:

- **Week 0:** NS
- **Week 3:** NS
- **Week 6:** P = .013
- **Week 9:** P < .001
- **Week 12:** P < .001

---

*NEW* **Aczone (dapsone) gel, 7.5%**

*For topical use only*

90g
ACZONE 7.5% – Safe and Well Tolerated

Incidence of Local Cutaneous Irritation in Controlled Clinical Trials for ACZONE® Gel, 7.5% Patients Whose Irritation Score was Higher than at Baseline (N=2161)

<table>
<thead>
<tr>
<th>Local Cutaneous Irritation</th>
<th>Before Treatment (baseline)</th>
<th>Maximum Severity (during treatment)</th>
<th>End of Treatment (Week 12)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mild</td>
<td>Moderate</td>
<td>Severe</td>
</tr>
<tr>
<td>Erythema</td>
<td>22%</td>
<td>8%</td>
<td>1%</td>
</tr>
<tr>
<td>Scaling</td>
<td>9%</td>
<td>1%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Dryness</td>
<td>13%</td>
<td>2%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Stinging/burning</td>
<td>15%</td>
<td>5%</td>
<td>1%</td>
</tr>
</tbody>
</table>
Additional Therapeutic and Cosmetic Indication to Provide $1B+ in Revenues

- Go **deeper** in toxins with new *indications & categories*
- Potential new toxins and formulations
- Undisclosed indications not included

<table>
<thead>
<tr>
<th>Options</th>
<th>Preclinical / Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Marketed*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-Op Atrial Fibrillation</td>
<td>New Toxin (2)</td>
<td>Premature Ejaculation</td>
<td>Overactive Bladder (Pedes)</td>
<td>Overactive Bladder</td>
</tr>
<tr>
<td>Platysma</td>
<td>New Toxin (1)</td>
<td>Major Depression</td>
<td>NDO (Pedes)**</td>
<td>Glabellar Lines</td>
</tr>
<tr>
<td></td>
<td>MT10109 Liquid</td>
<td>Knee Osteoarthritis</td>
<td>Forehead Lines</td>
<td>Crows Feet Lines</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Masseter Hypertrophy</td>
<td>Juvenile Cerebral Palsy (US)</td>
<td>Axillary Hyperhidrosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NDO (Pedes)**</td>
<td>Chronic Migraine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Overactive Bladder</td>
<td>Cervical Dystonia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lower Limb Spasticity</td>
<td>Upper Limb Spasticity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lower Limb Spasticity</td>
<td>Lower Limb Spasticity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Juvenile Cerebral Palsy</td>
<td>Upper Limb Spasticity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Strabismus</td>
<td>Cervical Dystonia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Axillary Hyperhidrosis</td>
<td>Cervical Dystonia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Blepharospasm</td>
<td>Glabellar Lines</td>
</tr>
</tbody>
</table>

* All worldwide, except Ex-US Only for Juvenile Cerebral Palsy & Lower Limb Spasticity
** Neurogenic Detrusor Overactivity (Bladder)
Expanding into Shaping and Contouring

VYCROSS collection is the next generation Filler

- VOLUMA is the first product from the VYCROSS collection and has become the #1 Filler US and Globally
- Next generation of High and Low MW HA technology
- Smooth, long-lasting formulation for differentiated results

Further indications in facial shaping will address younger market needs and overall aging concerns

- Chin Augmentation
- Temples to complement cheeks for Pan-facial age-related volume loss

Current Products
- Voluma Cheeks
- Juvederm Ultra Lips

Future US Products
- Voluma Chin & Jawline
- Voluma Temple

Wrinkles & Folds
- Juvederm Ultra
- Juvederm Ultra Plus

Volbella
- Volift
- Volite
Scale and Leadership Gives Us Expansion Opportunities into Multi-Billion Dollar Adjacencies by 2020

Medical Aesthetics ➔ Dermatology Area

- **$3.1B** Topical Acne
- **$2.7B** Dermal Facial Fillers
- **$2.4B** Cosmetic Neuromodulator
- **$1.6B** Emerging Technologies
- **$1.5B** Physician Dispensed Topicals
- **$1.5B** Breast Aesthetics
- **$0.2B** Eyelash Growth
- **$0.2B** Hyper-pigmentation
- **$0.4B** Alopecia
- **$0.1B** Scar Tx
- **$1.5B** Dermatitis
- **$9.1B** Psoriasis

Allergan presence

- Blue circle
- No / Limited Allergan presence

Figures are illustrative

Source: EvaluatePharma, IMS Analytics Link, Medical Insight Report
OPEN SCIENCE in Action

Underlying Logic behind Eye Care Strategy

Use Open Science Model to Sustain Leadership

Leading Therapies In:
- Dry Eye
- Glaucoma
- Retina
Delivering and Building the Eye Care Pipeline

- Oculeve acquisition – device to strengthen our dry eye pipeline portfolio
- AqueSys acquisition adds to our glaucoma pipeline
- Mimetogen in-license – another addition to dry eye franchise
- Ozurdex® (dexamethasone intravitreal implant) market expansion – approvals internationally
- DARPin® DME results
Restasis® Multi-Dose Preservative Free is an Important Innovation

- First Allergan product to be launched in this multi-dose bottle
  - ✓ Same formulation currently marketed RESTASIS®
  - ✓ Improved patient convenience
    - 1-month supply = 1 bottle vs 60 unit-dose vials
  - ✓ No new clinical trials needed; CMC Prior Approval Supplement (PAS) pathway for approval and launch
  - ✓ US PAS submission 2015

Current Restasis in the Mkt

Restasis MDPF

Patients prefer multi-dose bottles to single unit vials*

*Results are based on a small sample size (n=25) and directional in nature
OCULEVE: The First Dry Eye Ophthalmic Electroceutical
OCULEVE Increases Tear Production and Improves Symptoms

Initial Label:
Increased Tear Production

RCT in Sacramento, CA, USA, N = 16

* p < 0.05
Bimatoprost SR: Development Status

- Phase 2 Completed → results to be presented at American Academy of Ophthalmology (AAO) on November 15, 2015

- Interim Results highlights from a 24-Month Phase 1/2 Clinical Trial

Phase 1/2 interim data show that bimatoprost SR has favorable efficacy / safety and may change the treatment paradigm for glaucoma, addressing the problem of patient nonadherence
OZURDEX: New Data Presented at the American Academy of Ophthalmology (AAO)

- Data from Protocol I study will be presented at AAO week of November 13-17, 2015
- Data implies that trajectory of response to an ant-VEGF is on average 3 months
Overview of Pilocarpine/Oxymetazoline Presbyopia Program

- Presbyopia, the progressive loss of ability to focus at near with age, is a large and growing market.
- Goal of presbyopia program is to develop a non-invasive, reversible, pharmacologic treatment of presbyopia based on fixed combination of pilocarpine and oxymetazoline.
- In-licensed IP from AltaVista (Dr. J. Abad) based on results of observational studies conducted in Colombia with combination of pilocarpine and oxymetazoline.
- Recently completed analysis of a phase 2 POC study (199201-007) further supports safety and efficacy of combination of pilocarpine and oxymetazoline as a treatment of presbyopia.
- Based on positive POC study results, preparing to initiate two Phase 2b studies: 199201-009 and 199201-010.
Uncorrected Near Visual Acuity (UNVA): (Change in number of lines from baseline)

- Younger patients robustly respond to combination with 2.8 to 3.8 lines of improvement on average. This effect size is clinically significantly different from pilocarpine alone (Group 2).

![Graph showing the change in UNVA from baseline over time for different groups.](image)
Allergan/Molecular Partners; Collaboration for Success

- Create and develop Designed Ankyrin Repeat Proteins in ophthalmology
  - Abicipar pegol
  - Anti-VEGF/anti-PDGF DualDARPIn® AMD
  - Earlier discovery & pre-clinical-stage collaboration targets
- DARPIn® technology provides opportunity for highly-differentiated, next-generation drugs for multi-factorial ocular disease
- Collaborative development process leverages unique expertise of each partner
### DARPin® (Abicipar Pegol) Development Status

#### DME

**Study 150998-004 PALM**
- 2mg every 8 or 12 weeks
- 1 mg every 8 weeks and compared to Lucentis
- Initial topline DME results supports 12-wks duration with safety comparable to AMD studies

#### AMD

**Two Phase 3 studies initiated in Q2 2015**
- Randomized, double-masked, parallel-group, active controlled studies vs. ranibizumab
- Global studies with approximately 400 clinical study sites identified in total across approximately 30 countries, including Japan
- Recruitment in progress

**2 small phase 2 studies to compare between Japanese and non-Japanese patients**
- CYPRESS study
- BAMBOO study
Eye Care Market Poised for Growth

The number of treated patients is expected to increase due to an aging population and the expansion of access to health care.

Dry Eye market expansion with more therapeutic options.

Advances in drug delivery and devices address key barriers and re-ignite growth in glaucoma.

Market expansion opportunities with new products in underserved diseases – e.g., presbyopia, blepharitis, viral conjunctivitis, MGD.

Growth in surgical market will increase utilization of anti-inflammatories.

Generic alternatives and cost-control measures.

Source: IMS Health Eye Care Market Report 2009-2015; Team Thinking; GBI Ophthalmology Tx in Major Developed Markets to 2019 (2013); 2016 Retina Growth Plan
**Glaucoma Market is Poised for Transformation**

**Leader in the $1.9B US branded topical market**


- **Allergan**: 57%
- **Novartis**: 35%
- **Valeant**: 4%
- **Pfizer**: 2%

**US Glaucoma Treatment Dollar Share (2014)**

- **Topical Drops**: 93%
- **Other**: 3.8%
- **Sustained Delivery**: 3.5%
- **MIGS**: 64%

**MIGS Devices expected to grow at 42% p.a. between 2014 and 2020**

Our glaucoma pipeline capitalizes on the shift towards a dropless market:

- **Drug**
  - **Drug Delivery**
    - Bimatoprost SR
  - **Conventional Glaucoma Surgery**
  - **MIGS Devices**
    - AqueSys Xen

Better compliance, better efficacy, better economics.

Source: IMS Data, Market Scope, Internal Analysis
Best in Class Dry Eye Product Line

Low Rx penetration in Large Dry Eye Market

Expansion Opportunities Exist in All Severities
2015 - Current Use of Prescription Medication For Dry Eye by Severity of Symptoms (Among dry eye sufferers, n=776)

Source: 2015 Gallup Study, Market Scope, Internal Analysis
6 New Dry Eye Opportunities to Accelerate Growth
Further Expansion into Retina Will Allow us to Fully Participate in the $24B Eye Care Market in 2020

Eye Care

$14B
Retina

$3B
Therapeutic Dry Eye

$3.5B
Glaucoma

$0.5B
Inflammation

$1B
Anti-Infectives

$2B
All Others

Figures are illustrative
Source: EvaluatePharma, IMS Analytics Link
Allergan has High R&D Productivity vs Peers


1 Includes NMEs from all subsidiaries, pro-forma R&D spend
   SOURCE: Evaluate; Capital IQ; FDA; Press search
## Peak Sales of New Products up to $15B

<table>
<thead>
<tr>
<th>Product</th>
<th>TA</th>
<th>Indication</th>
<th>Expected Launch</th>
<th>Preliminary Peak Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABICIPAR</td>
<td>Eye Care</td>
<td>Age Related Macular Degeneration</td>
<td>2020</td>
<td>~$1,000–2,000+</td>
</tr>
<tr>
<td>RAPASTINEL</td>
<td>Psychiatry</td>
<td>Depression</td>
<td>2020</td>
<td>~$1,000–2,000+</td>
</tr>
<tr>
<td>BOTOX PIPELINE</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>~$1,000–2,000+</td>
</tr>
<tr>
<td>ORAL CGRP</td>
<td>Neurology</td>
<td>Migraine</td>
<td>2019</td>
<td>~$1,000–2,000</td>
</tr>
<tr>
<td>VIBERZI</td>
<td>GI</td>
<td>IBS-D</td>
<td>2015</td>
<td>~$750–1,000</td>
</tr>
<tr>
<td>ESMYA</td>
<td>WH</td>
<td>Uterine Fibroids</td>
<td>2017</td>
<td>~$500–1,000</td>
</tr>
<tr>
<td>RELAMORELIN</td>
<td>GI</td>
<td>Gastroparesis</td>
<td>2018</td>
<td>~$500–1,000</td>
</tr>
<tr>
<td>VRAYLAR</td>
<td>CNS</td>
<td>Bipolar Schizophrenia</td>
<td>2015</td>
<td>~$500–1,000</td>
</tr>
<tr>
<td>KYBELLA</td>
<td>Aesthetics</td>
<td>Chin Fullness</td>
<td>2015</td>
<td>~$500–1,000</td>
</tr>
<tr>
<td>BIMATOPROST SR</td>
<td>Eye Care</td>
<td>Glaucoma</td>
<td>2018</td>
<td>~$500–750</td>
</tr>
<tr>
<td>XEN45</td>
<td>Eye Care</td>
<td>Glaucoma</td>
<td>2016</td>
<td>~$500–750</td>
</tr>
<tr>
<td>TAVILERMIDE</td>
<td>Eye Care</td>
<td>Dry Eye</td>
<td>2019</td>
<td>~$500–750</td>
</tr>
<tr>
<td>SARECYCLINE</td>
<td>Derm</td>
<td>Severe Acne</td>
<td>2017</td>
<td>~$250–300</td>
</tr>
</tbody>
</table>